Pomalidomide-C7-COOH

Background Introduction

Pomalidomide-C7-COOH is a bifunctional molecule specially designed for next-generation PROTAC (Proteolysis Targeting Chimera) and targeted protein degradation applications. As a derivative of pomalidomide—a well-known ligand for the E3 ubiquitin ligase cereblon (CRBN)—this product features an extended C7 aliphatic linker and a carboxylic acid functional group. Its structure enables flexible PROTAC design and improved pharmacokinetic profiles, making it a high-value building block for drug discovery.

Mechanism

The mechanism of Pomalidomide-C7-COOH centers on its ability to recruit the CRBN E3 ubiquitin ligase. When conjugated to a target protein ligand via its reactive carboxylic acid group, it forms part of a PROTAC molecule. The PROTAC simultaneously binds the target protein and CRBN, positioning them in proximity. This induces ubiquitination of the target protein, marking it for selective proteasomal degradation. This catalytic event results in efficient and sustained reduction of the disease-relevant protein.

Applications

Pomalidomide-C7-COOH is widely utilized as an E3 ligase ligand-linker conjugate in the synthesis of custom PROTACs and targeted protein degraders. Its distinct structure with a C7 linker enables optimal spatial arrangement between the E3 ligase and target proteins, making it ideal for drug discovery, preclinical research, and chemical biology studies. Researchers leverage Pomalidomide-C7-COOH to facilitate the development of novel therapeutics against cancer, neurodegenerative disorders, and other diseases involving dysregulated proteins.